Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 October 2018, 07:00 HKT/SGT
Share:
        

Source: Novotech / Clinical Network Services (CNS)
Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Asia-Pacific CRO Novotech has acquired Australasian specialist CRO Clinical Network Services (CNS), with a mutual mission to expand services

SYDNEY, Oct 19, 2018 - (ACN Newswire) - Novotech, the largest Asia-Pacific-based CRO, has acquired Australasian specialist CRO Clinical Network Services (CNS), as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials. Both companies will continue to retain their separate brands and identities.

Early phase CNS clients, wishing to advance into later phase regional trials, can tap into Novotech's Asia-Pacific expertise backed by 10 partnership agreements with leading hospitals and medical institutions, offering access to 1.4 billion people living in urban areas across the region. Novotech has 400+ staff across Asia-Pacific and business development offices in the USA. CNS has more than 140 staff in Australia, New Zealand and the USA.

As part of the deal, clients can access leading services from both groups, including the CNS BioDesk, which provides early stage product development advice including toxicology, CMC and FDA/EMA regulatory consulting and interactions; and Novotech's advanced regional IT infrastructure, to support their clinical research programs.

Novotech CEO John Moller said:

"Biopharma clients should know this acquisition is a bringing together of the highest quality CROs in the region. Very importantly, we have developed remarkably similar company cultures, and I know the teams are excited about the opportunity of working together.

"Novotech and CNS will continue to operate under separate brands with CNS specialising in early phase non-oncology clinical trials across Australia and New Zealand, and Novotech specialising in regional Asia-Pacific and global project delivery across all phases.

"Our Asia-Pacific in-country relationships enable a comprehensive understanding of local regulatory requirements and changes, access to leading investigators, strong site connections, and accessible patient populations to deliver success for our clients within timelines and budgets."

CNS Managing Director Russ Neal commented:

"Early phase research in Australasia has seen incredible growth over the last 6-7 years and CNS is proud to be a significant part of this proven capability. As our clients have experienced success with us, we have often wished we had the international reach to continue supporting them.

"This truly complimentary association with Novotech now means that we are able to offer our clients access to Novotech's Asia-Pacific experience and expertise in later phase regional or global trials. On the other hand, Novotech clients can access our highly regarded global product development and regulatory affairs consultancy team, BioDesk, based out of Washington DC, London and Australia"

CNS COO and Executive Director Gabrielle McKee further added:

"CNS clients will also benefit from many of Novotech's strengths, including IT infrastructure and specialist functions such as legal, learning and development, marketing and analytics,. and particularly exciting, CNS and Novotech offer our clients one of the most experienced and knowledgeable biometrics teams in the region, with 70 staff in the combined unit."

About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia-Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia-Pacific presence includes running clinical trials in all key regional markets, with a worldwide reach through the company's network of strategic partners.

About Clinical Network Services (CNS) - https://clinical.net.au/
Clinical Network Services (CNS) is an integrated service group focused on product development. Headquartered in Australia, with offices in New Zealand, the UK and the USA, CNS creates value for small to medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

CNS offers a unique service, integrating BioDesk, an intelligent global product development and regulatory affairs consultancy, with its committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS' regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.

CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables it to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.

Media Contact:
Susan Fitzpatrick-Napier
communications@novotech-cro.com
USA: +1 415 951 3228
AUS: +61 2 8218 2144
ASIA: +65 3159 3427



Oct 19, 2018 07:00 HKT/SGT
Topic: Clinical Trial Results
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
INNO@CHUNWO Succeeds In Developing R2M2 - Enhances Efficiency of Repairing Old Buildings  
Jan 21, 2019 20:50 HKT/SGT
HKTDC Education & Careers Expo Opens on Thursday  
Jan 21, 2019 19:00 HKT/SGT
Kinetic Mines Issued Positive Profit Alert; Expected 40% Growth in the Net Profit for 2018   
Jan 21, 2019 16:54 HKT/SGT
SDK's 3.5-inch Media Now Used in World's-Largest-Capacity 16TB HDD  
Jan 21, 2019 13:00 HKT/SGT
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer  
Jan 21, 2019 13:00 HKT/SGT
Hong Kong ESG Reporting Awards 2019 Announces Partnerships with CUHK Jockey Club Museum of Climate Change and SDSN Hong Kong  
Jan 21, 2019 12:00 HKT/SGT
MHPS Opens "Remote Monitoring Center" in the Main Office of Its Nagasaki Works  
Jan 21, 2019 10:40 HKT/SGT
China Resources Power and Black Spade Capital sign a strategic joint venture cooperation agreement; teaming up to create an environmentally friendly world  
Jan 21, 2019 09:04 HKT/SGT
Mega Expo Subsidiary ME International Undertakes Large MICE Event in China Again  
Jan 18, 2019 19:53 HKT/SGT
TOYOTA GAZOO Racing trio take on the WRC's legendary curtain-raiser  
Jan 18, 2019 17:23 HKT/SGT
More Press release >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: